SML0720

醋甲唑胺

≥98% (HPLC)

• 同義詞: N-(4-甲基-2-氨基磺酰基-Δ²-1,3,4-噻二唑-5-亚基)乙酰胺
• 經驗公式（希爾表示法）: C₅H₈N₄O₃S₂
• CAS號碼: 554-57-4
• 分子量：: 236.27
• EC號碼: 209-066-7
• MDL號碼: MFCD00083416
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329825590
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 儲存條件: protect from light
• 顏色: white to beige
• mp: 208 °C (dec.) (lit.)
• 溶解度: DMSO: 20 mg/mL, clear
• 儲存溫度: 2-8°C
• SMILES 字串: CN1N=C(S\C1=N\C(C)=O)S(N)(=O)=O
• InChI: 1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4+
• InChI 密鑰: FLOSMHQXBMRNHR-QPJJXVBHSA-N
• 基因資訊: human ... CA1(759) , CA2(760) , CA4(762) , CA7(766)

描述

生化／生理作用

Cell-permeable and potent carbonic anhydrase (CA) inhibitor

Methazolamide has a plasma half-life of 14 hours in humans. Methazolamide has relatively good lipid solubility and low plasma protein binding ability. Thus, it diffuses into tissues and fluids much more readily than acetazolamide, another carbonic anhydrase inhibitor. Methazolamide has less side effects than acetazolamide.

Methazolamide is a cell-permeable and potent carbonic anhydrase (CA) inhibitor that is used in the treatment of glaucoma. Methazolamide is an insulin sensitizer that reduces hepatic glucose generation in animal models.

其他說明

Light sensitive

安全資訊

• 象形圖: GHS08,GHS07
• 訊號詞: Warning
• 危險聲明: H302 + H312 + H332,H351
• 防範說明: P202 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P308 + P313
• 危險分類: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 2
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3